T W Ho

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi request reprint Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
    T W Ho
    Merck Research Laboratories, UG 4C 18, PO Box 1000, North Wales, PA 19454 1099, USA
    Neurology 70:1304-12. 2008
  2. doi request reprint Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies
    T W Ho
    Merck and Co, Inc, UG4C 96 P O Box 100, North Wales, PA 19454, USA
    Pain 141:19-24. 2009
  3. doi request reprint Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
    Tony W Ho
    Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Lancet 372:2115-23. 2008
  4. doi request reprint Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults
    T W Ho
    Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cephalalgia 29:711-8. 2009

Detail Information

Publications4

  1. ncbi request reprint Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine
    T W Ho
    Merck Research Laboratories, UG 4C 18, PO Box 1000, North Wales, PA 19454 1099, USA
    Neurology 70:1304-12. 2008
    ..To determine an effective and tolerable dose of a novel oral calcitonin gene-related peptide (CGRP) receptor antagonist, MK-0974, for the acute treatment of migraine...
  2. doi request reprint Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies
    T W Ho
    Merck and Co, Inc, UG4C 96 P O Box 100, North Wales, PA 19454, USA
    Pain 141:19-24. 2009
    ..We conclude that gabapentin and tramadol were effective in the treatment of painful SFN and that this experimental enrichment paradigm is attractive to screen potential neuropathic pain compounds for efficacy in proof-of-concept studies...
  3. doi request reprint Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
    Tony W Ho
    Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Lancet 372:2115-23. 2008
    ..We aimed to assess the clinical profile of MK-0974 (telcagepant), an orally bioavailable antagonist of CGRP receptor...
  4. doi request reprint Age effects on placebo response rates in clinical trials of acute agents for migraine: pooled analysis of rizatriptan trials in adults
    T W Ho
    Merck Research Laboratories, North Wales, PA 19454 1099, USA
    Cephalalgia 29:711-8. 2009
    ..Age appeared to be an important predictor of placebo response rate in rizatriptan trials, with older patients being less likely to respond to placebo and more likely to respond to rizatriptan...